We find a way
Cerevel Therapeutics relentlessly finds paths through complexity to bring real progress and new treatment options to people living with a broad range of neurological and neuropsychiatric disorders.
Changing the course of disease
Many hypotheses have been advanced to better understand chronic neurological and neuropsychiatric disease progression, but attempts to develop therapeutics that modify or cure have been largely unsuccessful. Those failures have driven a retrenchment in pharmaceutical company investment in the space, leaving patients with limited options.
We have a clear vision for what’s next in neuroscience innovation combined with the unique flexibility to make clinical and commercial decisions for each compound without the financial restrictions of large pharma.
This freedom opens up opportunities to bring better and faster innovation to people living with neurological and neuropsychiatric diseases. It allows us to advance our portfolio of novel agents simultaneously, addressing key symptoms of chronic illnesses while investing in earlier stage compounds with biological hypotheses that can change the course of disease.
Unlocking what’s next
Our assets are highly specific solutions to biological hypotheses the industry has tried to tackle for years. They are the result of great ideas, deep neuroscience expertise, and chemical design over a 20 year period at Pfizer. As a standalone neuroscience company, we will push the boundaries of scientific understanding and impact.
Goal one is to efficiently bring to market our late-stage clinical assets focused in the areas of Parkinson’s Disease (dopamine D1 agonist) and Epilepsy (GABA A positive modulator).
In parallel, we will continue to advance our earlier stage pipeline across the spectrum of neurological and neuropsychiatric disorders—from Alzheimer’s Disease agitation/aggression to schizophrenia, depression and substance use disorder—and actively seek opportunities to expand and accelerate this portfolio through value added partnerships as well as M&A activity.